Free shipping on all orders over $ 500

Umbralisib

Cat. No. M5268

All AbMole products are for research use only, cannot be used for human consumption.

Umbralisib Structure
Synonym:

TGR-1202; RP5264

Size Price Availability Quantity
5mg USD 113 In stock
10mg USD 205 In stock
25mg USD 440 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively.

In vitro: Umbralisib (TGR-1202) displays a high degree of selectivity over the alpha (>1000 fold), beta (>30-50 fold), and gamma (>15-50 fold) isoforms. Additionally, Umbralisib (TGR-1202) causes a half-maximal inhibition of human whole blood CD19 cell proliferation between 100-300 nM. Treatment of PBMC with RP5264 results initially in a G2/M arrest followed by subsequent increase in the number of Sub G0 cells. Umbralisib (TGR-1202) causes a significant inhibition in growth as well as Akt phosphorylation of immortalized and primary leukemic cells.

In vivo: Umbralisib (TGR-1202) exhibits good oral absorption with favourable pharmacokinetic properties in rodents. It also has an excellent safety profile.

Protocol (for reference only)
Cell Experiment
Cell lines Multiple Myeloma resistant (MM-1R) or sensitive (MM-1S) cells
Preparation method Multiple Myeloma resistant (MM-1R) or sensitive (MM-1S) cells are incubated with desired concentrations of RP5264. Growth is assessed after 96 h by a MTT assay.
Concentrations
Incubation time 96 h
Animal Experiment
Animal models Female Balb/c mice
Formulation
Dosages 12.5, 25, 50 mg/kg
Administration p.o.
Chemical Information
Molecular Weight 571.55
Formula C31H24F3N5O3
CAS Number 1532533-67-7
Solubility (25°C) DMSO 25 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Deng C, et al. Blood. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

[2] Locatelli SL, et al. Leukemia. The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.

Related PI3K Products
AS605240

AS-605240 is a potent and selective inhibitor of PI 3-kinase γ (PI3Kγ) with an IC50 of 8 nM.

BEZ235

BEZ235 (NVP-BEZ235) is a potent dual PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively.

BKM120 (Buparlisib)

BKM120 (NVP-BKM120) is a potent and highly specific oral pan-class I PI3K inhibitor.

GDC-0941 (Pictilisib)

GDC-0941 is a selective and potent inhibitor of Class I PI3K, p110a IC50=0.003uM, U87MG IC50=0.95μM.

AS-252424

AS-252424 is a furan-2-ylmethylene thiazolidinedione as a selective ATP-competitive PI3Kγ inhibitor with IC50 with 33 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Umbralisib, TGR-1202; RP5264 supplier, PI3K, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.